Abstract
Materials development for biological implants and in vivo controlled delivery has historically focused on minimizing immunostimulation and resulting inflammation. Biomaterials are therefore usually optimized to inhibit the activation of inflammatory immune cell populations in tissues and biological fluids, decrease toxicity, increase the therapeutic efficacy of delivered agents, and extend the lifetime of implanted devices. More recently, instead of a focus on preventing inflammation, advances in the development of macro- and nanoscale biomaterials permit the direct elicitation of therapeutically beneficial responses from the immune system. Biomaterials provide numerous advantages for the administration of therapeutics, particularly as carriers for immunomodulatory agents that stimulate specific immune cell populations. These various methods of cellular targeting have proven to be highly advantageous for controlled stimulation of the immune system for both vaccination and cancer immunotherapy. Here, we discuss key concepts and biomaterials platforms to elicit therapeutic immunostimulation during the treatment of cancer.
Original language | English (US) |
---|---|
Title of host publication | Biomaterials for Cancer Therapeutics |
Subtitle of host publication | Evolution and Innovation |
Publisher | Elsevier |
Pages | 471-497 |
Number of pages | 27 |
ISBN (Electronic) | 9780081029831 |
ISBN (Print) | 9780081029848 |
DOIs | |
State | Published - Jan 1 2020 |
Keywords
- Immunostimulation
- biomaterials
- controlled delivery
- dendritic cell
- immunotherapy
- macrophage
- nanobiomaterials
- nanomaterials
- nanoparticles
ASJC Scopus subject areas
- General Medicine
- General Biochemistry, Genetics and Molecular Biology